Treatment of low back pain with a herbal or synthetic anti-rheumatic: A randomized controlled study. Willow bark extract for low back pain

Revmatologiia

Volumn 40, Issue 12, 2001, Pages 1388-1393

  Chrubasik, S ^a,b,e   Kunzel O ^b   Model, A ^b   Conradt, C ^c   Black, A ^d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e UNIVERSITY OF FREIBURG   (Germany)

Author keywords

COX 2 inhibitor; Low back pain; Randomized controlled study; Willow bark

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; ASSALIX; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; HERBACEOUS AGENT; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PLANT EXTRACT; ROFECOXIB; SALICIN; TRAMADOL;

ADULT; AGED; ALLERGY; ARTICLE; ASTHMA; BARK; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; EDEMA; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEAT SENSATION; HUMAN; INCIDENCE; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PAIN ASSESSMENT; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VERTIGO; VISUAL ANALOG SCALE; WILLOW;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; FEMALE; GERMANY; HUMANS; LACTONES; LOW BACK PAIN; MALE; MIDDLE AGED; PLANT EXTRACTS; PLANT PREPARATIONS; PRODUCT SURVEILLANCE, POSTMARKETING; SULFONES;

EID: 0035681660     PISSN: 13100505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Burton AK, Waddell G. Clinical guidelines in the management of low back pain. Bailliere's Clin Rheumatol 1998;12:17-35.
2. Van Tulder MW, Koes BW, Bouter LM. Conservative treatment of acute and chronic nonspecific low back pain. Spine 1996;22:2128-56.
3. Raskin JB. Gastrointestinal effects of nonsteroidal anti-inflammatory therapy. Am J Med 1999; 106(5B): 3-12S.
4. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drues: Physiologic foundations and clinical implications. Am J Med 1999;106(5B):13-24S.
5. Langman MJ, Jensen DM, Watson DJ et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. J Am Med Assoc 1999;282:1929-33.
6. Chrubasik S, Eisenberg E, Balan E, Weinberger T, Conradt C. Treatment of low back pain exacerbations with willow bark extract: a randomized double-blind study. Am J Med 2000; 109:9-14.
7. Ernst E, Chrubasik S. Phyto-anti-inflammatories. A systematic review of randomized, placebo-controlled, double-blind trials. Rheum Dis Clin N Am 2000;26:13-27.
8. Schmid BM. Behandlung von Cox- und Gonarthrosen mit einem Trockenextrakt aus Salix purpurea and daphnoides. PhD thesis, University of Tübingen, 1998.
9. Chrubasik S, Künzel O, Black A, Conradt C, Kerschbaumer F. Potential economic impact of using a proprietary willow bark extract in outpatient treatment of low back pain: an open non-randomized study. Phytomedicine 2001;8:241-51.
10. Day R, Morrison B, Luza A et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med 2000;160:1781-7.
11. Cannon GW, Caldwell JR, Holt P et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Phase III Protocol 035 Study Group. Arthritis Rheum 2000;43:978-87.
12. ESCOP Monographs. Salicis cortex. Exeter: ESCOP Monograph Binder. IISBN 1-901964-03-5.
13. Chrubasik S, Fiebich B, Black A, Pollak S. Treating low back pain with a Salix extract that inhibits COX-2 and the release of cytokines. Eur J Anaesthesiol Suppl; in press.
14. Goldring MB. The role of cytokines as inflammatory mediators in osteoarthritis: lessons from animal models. Connect Tissue Res 1999;40:1-11.